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Aims Although non-vitamin K antagonist oral anticoagulants are recommended for stroke prevention in patients with
non-valvular atrial fibrillation (NVAF) based on clinical trial results, there is a need for safety and efficacy data from
unselected patients in everyday clinical practice. XANTUS investigated the safety and efficacy of the Factor Xa inhibitor
rivaroxaban in routine clinical use in the NVAF setting.
Methods and
results
Consecutive consenting patients with NVAF newly started on rivaroxaban were eligible and were followed up at
3-month intervals for 1 year, or for at least 30 days after permanent discontinuation. All adverse events (AEs)
were recorded as AEs or serious AEs; major outcomes (including major bleeding, symptomatic thromboembolic events
[stroke, systemic embolism, transient ischaemic attack, and myocardial infarction], and all-cause death) were centrally
adjudicated. There were 6784 patients treated with rivaroxaban at 311 centres in Europe, Israel, and Canada. Mean
patient age was 71.5 years (range 19–99), 41% were female, and 9.4% had documented severe or moderate renal
impairment (creatinine clearance ,50 mL/min). The mean CHADS2 and CHA2DS2-VASc scores were 2.0 and 3.4,
respectively; 859 (12.7%) patients had a CHA2DS2-VASc score of 0 or 1. The mean treatment duration was 329
days. Treatment-emergent major bleeding occurred in 128 patients (2.1 events per 100 patient-years), 118 (1.9 events
per 100 patient-years) died, and 43 (0.7 events per 100 patient-years) suffered a stroke.
Conclusion XANTUS is the first international, prospective, observational study to describe the use of rivaroxaban in a broad
NVAF patient population. Rates of stroke and major bleeding were low in patients receiving rivaroxaban in routine
clinical practice.
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Introduction
Atrial fibrillation (AF) affects 2% of the European population, and
its prevalence is rising due to concomitant conditions and ageing po-
pulations.1 Stroke is one serious consequence of AF,2 but oral antic-
oagulation can prevent most cases of AF-related stroke.3,4 Although
the evidence supporting the use of anticoagulation for stroke pre-
vention in AF has been generated with dose-adjusted vitamin K an-
tagonists (VKAs), four non-VKA oral anticoagulants (NOACs) have
been found to be at least as effective and safer than VKAs for stroke
prevention in patients with non-valvular AF (NVAF).5 – 8 These
NOACs have been approved for use in this indication and are re-
commended as alternatives to VKAs in international guidelines.3,4
Further information on the effectiveness of NOACs is still
accumulating in the form of retrospective registries and additional
randomized clinical trials. A high volume of prospectively collected
information in large patient groups is still lacking. This was recog-
nized by the European Medicines Agency (EMA), leading to a re-
quirement to conduct observational studies as part of the
post-approval plan. Here, outcomes are reported from the
XANTUS study, which assessed the safety and efficacy of rivaroxa-
ban in routine, ‘real-world’ clinical practice.
Methods
The design of the international, non-interventional, observational
XANTUS study was approved by the EMA and details have been pub-
lished previously.9
Study population and screening
Eligible patients had a diagnosis of NVAF, were aged ≥18 years, started
rivaroxaban therapy to reduce the risk of stroke or systemic embolism
(SE), and provided written informed consent. All patients were
screened sequentially and documented in an anonymous log file inde-
pendent of therapy.
Medication and follow-up
Decisions about rivaroxaban prescription were at the discretion of the
treating physician, including dose and duration of therapy. Label-
recommended rivaroxaban doses for stroke prevention in NVAF are
20 mg once daily (od) for patients with normal renal function or mild
impairment (creatinine clearance [CrCl] ≥50 mL/min) and 15 mg
od for patients with moderate or severe renal impairment (CrCl
15–49 mL/min; e.g. in Europe). After the screening visit, follow-up
data collection was at the time of hospital discharge, if applicable, and
approximately every 3 months thereafter. The overall follow-up period
was 1 year. For patients who discontinued therapy before the end of the
1-year follow-up, the observation period ended 30 days after the last
dose of rivaroxaban.
Study outcomes
The primary outcomes were related to the safety of rivaroxaban, re-
corded as adverse events (AEs) or serious AEs (SAEs), and included ma-
jor bleeding events (defined using International Society on Thrombosis
and Haemostasis [ISTH] criteria), all-cause death, and any other AEs and
SAEs.9 Secondary outcomes included symptomatic thromboembolic
events (stroke, non-central nervous system SE, transient ischaemic at-
tack [TIA], and myocardial infarction [MI]) and non-major bleeding
events (defined as any bleeding event not meeting the criteria for a
major haemorrhage) across patients with different baseline risk profiles
for stroke or bleeding. Intracranial bleeding that met the definition of
stroke was included in both stroke and major bleeding endpoints.
Haemorrhagic transformations of ischaemic stroke were counted as a
major bleeding event regardless of whether symptomatic or not. Other
outcomes included treatment persistence, patient satisfaction (reported
by patients using standardized questionnaires), healthcare resource use,
and details of treatment interruption and interventions such as manage-
ment of bleeding events and stroke.
Study conduct
XANTUS applied several quality assurance measures. Physicians were
specifically requested to document at every visit if bleeding, stroke,
SE, TIA, MI, or other AEs had occurred, and this was captured as a
‘yes/no’ response for each event of interest. To detect unreported
events, the database was searched for concomitant medications, inter-
ventions, other key words, and laboratory findings potentially associated
with a bleeding or thromboembolic event. Questionable findings from
this search triggered medical queries to the investigator and potentially
central adjudication.
An independent Central Adjudication Committee (CAC) of five ex-
pert physicians (not directly involved in the care of XANTUS study pa-
tients) adjudicated major bleeding, stroke, SE, TIA, MI, and all-cause
death. The CAC had access to all patient records. Bleeding events
were documented by the investigators as AEs. A verified algorithm
was used to search the database for all recorded bleeding AEs that
were associated with transfusions, were fatal, occurred at a critical
site, were associated with an intervention, or were assessed as ‘major’
by the investigator. The algorithm also identified any recorded haemo-
globin decreases of ≥2 g/dL regardless of the documentation of an AE.
All cases identified via this algorithm were adjudicated by the CAC.
Thromboembolic events were also recorded as AEs. In cases of poten-
tial stroke, SE, TIA, or MI from either investigator assessment or a data-
base search, central adjudication was performed. The CAC also
adjudicated the type of stroke and occurrence of a haemorrhagic trans-
formation of ischaemic stroke. Clinical cause of death was centrally ad-
judicated. To ensure reporting standards, quality assessment and source
data verification visits were performed at 61 (19.6%) sites between Q4–
13 and Q3–14, and documentation related to 581 patients (8.6%) was
reviewed.
Study governance
The study complied with the Declaration of Helsinki, was approved by the
appropriate Health Authorities, independent Ethics Committees, and In-
dependent Review Boards as required, and was conducted in accordance
with Good Pharmacoepidemiological Practice (GPP). An independent
academic Steering Committee oversaw the design, execution, and con-
duct of the study, was responsible for manuscript development, had full
access to all data, and approved all versions of the manuscript.
Patients’ informed consent included the permission for data collection
and analysis. To minimize the risk of loss to follow-up, in countries where
this is permitted, patients could voluntarily provide an alternative contact
to the investigator/independent patient management team. In compliance
with Good Clinical Practice (GCP) standards, data management and stat-
istical analyses were overseen by the sponsor. The lead statistician over-
saw programming and validation of the statistical analyses.
Statistical analysis
Events were considered ‘treatment-emergent’ if they occurred from the
day of the first dose of rivaroxaban, and up to 2 days after the last dose in
the event of permanent discontinuation. Statistical analyses of the
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events were descriptive, exploratory, and generally limited to frequency
tables or summary statistics (e.g. mean+ standard deviation [SD] or
median+ quartiles). The primary analysis population was the full safety
population, defined as all patients who had taken at least one dose of
rivaroxaban. Both raw incidence proportions (patients with events/
number of treated patients) and incidence rates (events per 100 patient-
years) are presented, with corresponding 95% confidence intervals.
Results
Patient demographics and clinical
characteristics
A total of 10 934 patients were screened between June 2012 and
December 2013, of whom 6785 were enrolled from 311 centres
in Europe, Israel, and Canada. Most patients (5287 [77.9%]) were
from Western Europe, Canada, and Israel, with 1497 (22.1%) pa-
tients from Eastern Europe. One patient did not take rivaroxaban;
therefore, the analysis reported here is based on 6784 patients; of
whom, 5336 (78.7%) received rivaroxaban 20 mg od, 1410
(20.8%) received 15 mg od, and 35 (0.5%) received another dose
(information on dosing was missing in three patients; Figure 1).
The mean observation period was 329 (SD 115, median 366)
days. In total, 45.5% of patients had previous VKA use, 54.5%
were categorized as VKA naive, 18% had previously used acetylsali-
cylic acid (excluding combination therapies) for stroke prevention,
and 1.0% had received dual antiplatelet therapy alone. The baseline
demographics and clinical characteristics of patients are summarized
in Table 1. Mean patient age was 71.5 years; 37% of all patients were
aged .75 years, and 59% were male. Co-morbidities were com-
mon: 74.7% of patients had hypertension; 19.6% had diabetes;
19.0% had experienced a prior stroke, SE, or TIA; and 18.6% had
congestive heart failure. The mean CHADS2 score was 2.0 (median
2.0) and the mean CHA2DS2-VASc score was 3.4 (median 3.0).
There were 12.7% of patients who had a CHA2DS2-VASc score
of either 0 or 1; furthermore, 18.5% of patients were first diagnosed
with NVAF, 40.6% with paroxysmal AF, and 40.7% with persistent or
permanent AF.
Outcomes
In the cohort of 6784 patients, the overall numbers of major bleed-
ing and thromboembolic events and all-cause deaths were low
and increased progressively over time (Figure 2A). Most patients
Figure 1 Patient disposition during the study. *Reasons for not continuing in the study included, but were not limited to, patient decision and
administrative and medical reasons. Some patients could have more than one reason for exclusion. †Other dose includes any initial rivaroxaban
dose besides 15/20 mg once daily (excluding missing information, n ¼ 3).
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(6522 [96.1%]) did not experience any of the outcomes of
treatment-emergent major bleeding, all-cause death, or stroke/SE
(freedom from events; Figure 2B).
A total of 2709 patients (39.9%) had a treatment-emergent AE
and 1200 (17.7%) had a treatment-emergent SAE. There were
142 treatment-emergent major bleeding events in 128 patients
(2.1 events per 100 patient-years). The incidence rate of fatal bleed-
ing was 0.2 events per 100 patient-years; critical organ bleeding oc-
curred at a rate of 0.7 events per 100 patient-years, including
intracranial haemorrhage (0.4 events per 100 patient-years). The
incidence of major gastrointestinal bleeding was 0.9 events per
100 patient-years (Table 2). Stroke occurred in 43 (0.7 events per
100 patient-years) patients, with SE occurring in a further 8 patients
(0.1 events per 100 patient-years). Eleven patients (0.2%) had
a haemorrhagic stroke and 32 (0.5%) an ischaemic stroke. Left
atrial thrombus was recorded in six patients (0.1 events per
100 patient-years). All-cause death occurred in 118 patients
(1.9 events per 100 patient-years) within the study treatment peri-
od, with the adjudicated cause of death due primarily to cardiovas-
cular causes, mainly heart failure, followed by cancer (Table 3).
The incidence of major bleeding events increased with age and
occurred at a rate of 0.9 events per 100 patient-years in patients
aged ,65 years, 1.7 events per 100 patient-years in patients aged
≥65 to ≤75 years, and 3.2 events per 100 patient-years in those
aged .75 years. The corresponding rates for symptomatic
thromboembolic events (stroke/SE, TIA, and MI) were 0.8, 1.8,
and 2.3 events per 100 patient-years, respectively. Outcome analysis
according to CHADS2 and CHA2DS2-VASc risk scores showed that
stroke/SE, major bleeding, and all-cause death generally increased
with higher risk scores (Figure 3).
Creatinine clearance values were reported in 4452 (65.6%)
patients. Of these, 14.4% had CrCl ,50 mL/min and 85.6% had
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Table 1 Baseline demographics and clinical
characteristics of patients in the XANTUS study
Rivaroxaban
(N 5 6784)
Age (years), mean+ SD 71.5+10.0
Age ,65, n (%) 1478 (21.8)
Age ≥65 to ≤75, n (%) 2782 (41.0)
Age .75, n (%) 2524 (37.2)
Gender (male), n (%) 4016 (59.2)
Weight (kg), mean+ SD 83.0+17.3
BMI (kg/m2), mean+ SD 28.3+5.0
BMI .30, n (%) 1701 (25.1)
Creatinine clearance (mL/min), n (%)
,15 20 (0.3)
≥15 to ,30 75 (1.1)
≥30 to ,50 545 (8.0)
≥50 to ≤80 2354 (34.7)
.80 1458 (21.5)
Missing 2332 (34.4)
Existing co-morbidities, n (%)
Hypertension 5065 (74.7)
Diabetes mellitus 1333 (19.6)
Prior stroke/non-CNS SE/TIA 1291 (19.0)
Congestive HF 1265 (18.6)
MI 688 (10.1)
Hospitalization at baseline, n (%) 1226 (18.1)
AF, n (%)
First diagnosed 1253 (18.5)
Paroxysmal 2757 (40.6)
Persistent 923 (13.6)
Permanent 1835 (27.0)
Missing 16 (0.2)
CHADS2 score
Mean score+ SD 2.0+1.3
Score, n (%)
0 703 (10.4)
1 2061 (30.4)
2 2035 (30.0)
3 1111 (16.4)
4 618 (9.1)
5 222 (3.3)
6 34 (0.5)
Missing 0 (0.0)
CHA2DS2-VASc score
Mean score+ SD 3.4+1.7
Score, n (%)
0 174 (2.6)
1 685 (10.1)
2 1313 (19.4)
3 1578 (23.3)
4 1405 (20.7)
5 837 (12.3)
6–9 789 (11.6)
Missing 3 (,0.05)
Continued
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1 Continued
Rivaroxaban
(N 5 6784)
Prior use of antithrombotics, n (%)
VKA 2767 (40.8)
Direct thrombin inhibitor 208 (3.1)
Acetylsalicylic acid (excluding dual antiplatelet
therapy)
1224 (18.0)
Dual antiplatelet therapy 68 (1.0)
Factor Xa inhibitor (excluding rivaroxaban) 10 (0.1)
Heparin group 217 (3.2)
Other 55 (0.8)
Multiple 410 (6.0)
VKA
Experienced 3089 (45.5)
Naive 3695 (54.5)
CrCl calculated using the Cockcroft–Gault formula.
AF, atrial fibrillation; BMI, body mass index; CNS, central nervous system;
CrCl, creatinine clearance; HF, heart failure; MI, myocardial infarction; SD, standard
deviation; SE, systemic embolism; TIA, transient ischaemic attack; VKA, vitamin
K antagonist.
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CrCl ≥50 mL/min. As expected, rates of major bleeding were high-
est in patients with documented reduced renal function (3.4% in
patients with CrCl ,50 mL/min). The lowest incidence proportion
for major bleeding (0.6%) was observed in patients for whom no
CrCl test results were recorded. Of 3812 patients with a documen-
ted CrCl of ≥50 mL/min, 15% received the lower rivaroxaban dose
of 15 mg od; conversely, the 20 mg od dose was received by 36% of
the 640 patients who had moderate or severe renal impairment
documented at any time during the study. Outcomes of major
bleeding, all-cause death, or thromboembolic events (stroke, SE,
TIA, and MI combined) showed numerically higher incidence rates
for the 15 mg od dose compared with the 20 mg od dose: 3.1 vs. 1.8
events per 100 patient-years for major bleeding, 3.7 vs. 1.4 events
per 100 patient-years for all-cause death, and 2.3 vs. 1.6 events per
100 patient-years for thromboembolic events, respectively.
Additional outcomes
In total, 598 patients (8.8%) had at least one interruption of rivarox-
aban therapy, which was most commonly because of a need for sur-
gery, or because of bleeding or another AE. The median treatment
interruption period was 4 days (Q1–Q3; 2–12 days). Among all pa-
tients with treatment interruption, major bleeding was recorded in
5.2% during the interruption period or within 2 days of the end of
this period; thromboembolic events occurred in 2.0% of patients.
Interventions for stroke were rare: among 32 patients with ischae-
mic stroke, no thrombectomies were performed and two patients
underwent thrombolysis. Among 27 patients with MI, no thromb-
olysis was performed, but percutaneous intervention and coronary
artery bypass grafting were performed in 11 patients and two
patients, respectively. Major bleeding was mostly treated using con-
servative methods and non-specific reversal agents were rarely
Figure 2 (A) Cumulative rates (Kaplan–Meier) for treatment-emergent all-cause death, major bleeding events, and stroke/systemic embolism.
(B) Event-free rate (Kaplan–Meier) for treatment-emergent all-cause death, major bleeding events, and stroke/systemic embolism. In total, 6522
(96.1%) patients did not experience any of the outcomes of treatment-emergent all-cause death, major bleeding, or stroke/systemic embolism.
Safety analysis set.
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used; the use of prothrombin complex concentrate was documen-
ted in two patients, tranexamic acid in three patients, and etamsylate
in one patient. Treatment persistence remained high over the 1-year
study period, with a discontinuation rate at the end of the
observation period of 20.1%. This finding coincided with 5096
(75.1%) patients reporting to their physicians that they were ‘very
satisfied’ or ‘satisfied’ with their treatment. The main reason for pre-
mature discontinuation (7.9% of all patients) was the occurrence
of an AE.
Discussion
Studies such as XANTUS complement the outcomes of pivotal
trials through the use of unselected real-world populations and
conditions. XANTUS is the first international, prospective,
non-interventional study describing the use of a NOAC for stroke
prevention in a broad NVAF patient population. Whereas patients in
the phase III ROCKET AF trial had a mean CHADS2 score of 3.5,
with 55% having experienced prior stroke/SE or TIA,7 patients stud-
ied in XANTUS had a lower risk of stroke, with a mean CHADS2
score of 2.0 and 19.0% experiencing prior stroke/TIA or SE. The
baseline stroke risk of patients in XANTUS is, therefore, similar
to that of other NOAC trials, such as RE-LY and ARISTOTLE, in
which the mean CHADS2 score was 2.1, and the percentages of pa-
tients with a prior stroke were 20.0 and 19.4%, respectively.5,6
XANTUS included patients at a slightly lower baseline stroke risk,
with a lower percentage of patients with prior stroke than ENGAGE
AF-TIMI 48, for which values were 2.8 and 28.3%, respectively.8
With the distribution of stroke risk scores in XANTUS, real-
world stroke incidence was low in patients receiving anticoagula-
tion, with an annual stroke rate of 0.7% (vs. 1.7 events per 100
patient-years in the ROCKET AF on-treatment population). The in-
cidence rates of other thromboembolic events and for all-cause
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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Table 2 Adjudicated treatment-emergent
thromboembolic and bleeding events and
all-cause death
Rivaroxaban (N 5 6784)
Incidence
proportion,
n (%)
Incidence rate,
events per 100
patient-years
(95% CI)
All-cause death 118 (1.7) 1.9 (1.6–2.3)
Thromboembolic events
(stroke, SE, TIA, and MI)
108 (1.6) 1.8 (1.5–2.1)
Stroke/SE 51 (0.8) 0.8 (0.6–1.1)
Stroke 43 (0.6) 0.7 (0.5–0.9)
Primary haemorrhagic 11 (0.2)
Primary ischaemic 32 (0.5)
Haemorrhagic
transformation
3 (,0.05)
No haemorrhagic
transformation
29 (0.4)
Uncertain 0
SE 8 (0.1) 0.1 (0.1–0.3)
TIA 32 (0.5) 0.5 (0.4–0.7)
MI 27 (0.4) 0.4 (0.3–0.6)
Major bleeding 128 (1.9) 2.1 (1.8–2.5)
Fatal 12 (0.2) 0.2 (0.1–0.3)
Critical organ bleeding 43 (0.6) 0.7 (0.5–0.9)
Intracranial haemorrhage 26 (0.4) 0.4 (0.3–0.6)
Intraparenchymal 6 (0.1)
Subarachnoid 5 (0.1)
Intraventricular 6 (0.1)
Subdural haematoma 6 (0.1)
Epidural haematoma 1 (,0.05)
Haemorrhagic
transformation of
ischaemic stroke
3 (,0.05)
Missing 2 (,0.05)
Mucosal bleedinga 60 (0.9) 1.0 (0.7–1.3)
Gastrointestinal 52 (0.8) 0.9 (0.6–1.1)
Haemoglobin decrease
≥2 g/dLb
52 (0.8) 0.9 (0.6–1.1)
Transfusion of ≥2 units
of packed red blood
cells or whole bloodb
53 (0.8) 0.9 (0.6–1.1)
Non-major bleeding events 878 (12.9) 15.4 (14.4–16.5)
CI, confidence interval; MI, myocardial infarction; SE, systemic embolism; TIA,
transient ischaemic attack.
aThe numbers shown here are for major mucosal and gastrointestinal bleeding
events. Mucosal bleeding events include gingival, epistaxis, gastrointestinal, rectal,
macroscopic haematuria, and increased or prolonged menstrual or abnormal
vaginal bleeding.
bRepresents major bleeding.
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Table 3 Causes of treatment-emergent adjudicated
death
Adjudicated causes of death Number of patients
(N5 118a),
n (%)
Cardiovascular 49 (41.5)
Cardiac decompensation, heart failure 24 (20.3)
Sudden or unwitnessed death 14 (11.9)
MI 6 (5.1)
Non-haemorrhagic stroke 4 (3.4)
Dysrhythmia 1 (0.8)
Venous thromboembolism 0
Other vascular event 0
Cancer 23 (19.5)
Other 16 (13.6)
Bleeding 12 (10.2)
Extracranial haemorrhage 5 (4.2)
Intracranial bleeding 7 (5.9)
Infectious disease 10 (8.5)
Unexplained 9 (7.6)
MI, myocardial infarction.
aMultiple reasons were recorded for the cause of treatment-emergent adjudicated
death of some patients.
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death were also low in this unselected patient population. The inci-
dence rate of major bleeding was 2.1 events per 100 patient-years,
which is lower than in ROCKET AF (3.6 events per 100 patient-
years)7 and similar to that seen in a large US study of electronic med-
ical records of 27 467 patients (2.9 events per 100 patient-years),
although this study used a different bleeding definition.10 The major
bleeding rate was also similar to published data from the smaller,
real-world, observational Dresden NOAC Registry involving 1200
AF patients treated with rivaroxaban (3.1 events per 100 patient-
years).11 The incidence rates of fatal bleeding, critical organ bleed-
ing, and intracranial haemorrhage were similar to those observed
in ROCKET AF (XANTUS vs. ROCKET AF 0.2 vs. 0.2 events per
100 patient-years, 0.7 vs. 0.8 events per 100 patient-years, and
0.4 vs. 0.5 events per 100 patient-years, respectively), whereas ma-
jor gastrointestinal bleeding occurred less frequently (0.9 events per
100 patient-years) than that seen in ROCKET AF (2.0 events per
100 patient-years).12
Throughout the study, the use of non-specific reversal agents
(such as prothrombin complex concentrate) was low. This finding
is in line with outcomes from ROCKET AF and the Dresden
NOAC Registry,11,13 and suggests that these agents are rarely
used in clinical practice. The lowest incidence proportion of major
bleeding (0.6%) was observed in patients for whom no CrCl test re-
sults were recorded throughout the study, suggesting that labora-
tory testing may have been reserved for patients at higher risk,
and clinical assessment may have been judged appropriate in pa-
tients with overall acceptable health. Because this was an observa-
tional study, it is also possible that CrCl tests may have been
performed but not documented. The Executive Steering Commit-
tee specifically asked all investigators in a letter to document renal
function; however, it cannot be excluded that measured CrCl has
not been documented and this would contribute to the missing
data. In addition, major bleeding, all-cause death, and thrombo-
embolic events (stroke, SE, TIA, and MI combined) occurred at high-
er incidence rates for the 15 mg od vs. the 20 mg od dose, which
indicated that dosing decisions might have been based on other clin-
ical considerations besides impaired renal function.
Drug persistence is a major concern in stroke prevention be-
cause anticoagulant discontinuation potentially leaves patients un-
protected from the risk of stroke. Recent data obtained with
VKAs showed discontinuation rates of 32 and 38% at 6 and 12
months, respectively.14,15 Available data on NOACs suggest higher
persistence rates. Persistence with rivaroxaban in XANTUS was
80% at 1 year, which is higher than recent US studies14,15 but in
line with that observed in other real-world studies such as the
Dresden NOAC Registry, in which discontinuations of 15%
were recorded in the first year.16
There are some limitations to this real-world study. XANTUS
was a single-arm study and, as with any open-label study, the study
design can introduce bias related to knowledge about treatment.
Figure 3 Outcomes as a function of (A) CHADS2 and (B) CHA2DS2-VASc scores.
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In addition, patients agreeing to participate in the study may, to
some extent, have self-selected for risk of stroke or bleeding, and
conscientious participation, and a selection bias based around intact
cognitive function could have arisen with the investigator. Owing to
the observational design, interference with patient management,
such as reinforcement of laboratory and other investigations, was
not allowed. This led, for example, to a large number of patients
with unknown CrCl values. Although it was possible to assess per-
sistence, there was no possibility to assess drug adherence in a stan-
dardized fashion in an observational study. Finally, outcomes
per rivaroxaban dose were not adjusted for baseline risk factors
for this analysis.
Strengths of this study include its meaningful sample size and a
prospective design allowing for greater completeness of data and
potentially better data quality compared with retrospective designs.
The independent endpoint adjudication is expected to have reduced
reporting bias.
Conclusion
XANTUS is the first large, international, prospective study describ-
ing the use of rivaroxaban for stroke prevention in a broad NVAF
patient population. The rates of major bleeding and stroke with riv-
aroxaban were found to be low in routine clinical practice.
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